Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Longen Zhou"'
Autor:
Elaine Lai-Han Leung, Run-Ze Li, Xing-Xing Fan, Lily Yan Wang, Yan Wang, Zebo Jiang, Jumin Huang, Hu-Dan Pan, Yue Fan, Hongmei Xu, Feng Wang, Haopeng Rui, Piu Wong, Hermi Sumatoh, Michael Fehlings, Alessandra Nardin, Paul Gavine, Longen Zhou, Yabing Cao, Liang Liu
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-9 (2023)
Abstract Response to immunotherapy widely varies among cancer patients and identification of parameters associating with favourable outcome is of great interest. Here we show longitudinal monitoring of peripheral blood samples of non-small cell lung
Externí odkaz:
https://doaj.org/article/c845ab00de49468c83ac80f41f9fb0d6
Autor:
Jennifer Yang, Anand D Jeyasekharan, Joanne Lee, Wee Joo Chng, Tae-Hoon Chung, Nurulhuda Mustafa, Adina Huey Fang Nee, Jing Yuan Chooi, Sabrina Hui Min Toh, Viknesvaran Selvarajan, Shuangyi Fan, Siok Bian Ng, Michelle Poon, Esther Chan, Yen Lin Chee, Longen Zhou
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Background The potential therapeutic efficacy of daratumumab in natural killer T-cell lymphoma (NKTL) was highlighted when its off-label usage produced sustained remission in a patient with highly refractory disease. This is corroborated recently by
Externí odkaz:
https://doaj.org/article/9c459924e2a046e6b5b7572c0f5ce51a
Autor:
Jiewen Zhu, Longen Zhou, Guikai Wu, Heiko Konig, Xiaoqin Lin, Guideng Li, Xiao‐Long Qiu, Chi‐Fen Chen, Chun‐Mei Hu, Erin Goldblatt, Ravi Bhatia, A. Richard Chamberlin, Phang‐Lang Chen, Wen‐Hwa Lee
Publikováno v:
EMBO Molecular Medicine, Vol 5, Iss 3, Pp 353-365 (2013)
Abstract RAD51 recombinase activity plays a critical role for cancer cell proliferation and survival, and often contributes to drug‐resistance. Abnormally elevated RAD51 function and hyperactive homologous recombination (HR) rates have been found i
Externí odkaz:
https://doaj.org/article/ee25ef9b483a42d483e59c8e0149a2aa
Autor:
Wen-Hwa Lee, Phang-Lang Chen, Johnson Lau, Richard Chamberlin, Jiewen Zhu, Longen Zhou, Xiao-Long Qiu, Guikai Wu
Supplementary Figures 1-4 from Small Molecule Targeting the Hec1/Nek2 Mitotic Pathway Suppresses Tumor Cell Growth in Culture and in Animal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d957a8a4d525912e5c9d74c747ed3e8
https://doi.org/10.1158/0008-5472.22375733.v1
https://doi.org/10.1158/0008-5472.22375733.v1
Autor:
Run-Ze Li, Yue Fan, Haopeng Rui, Longen Zhou, Paul Gavine, Liang Liu, Hongmei Xu, Yabing Cao, Michael G. Fehlings, Ze-Bo Jiang, Piu Wong, Xing-Xing Fan, Alessandra Nardin, Hu-Dan Pan, Hermi Sumatoh, Elaine Leung, Yan Wang, Lily Yan Wang, Ju-Min Huang
The response to immunotherapy could be better predicted by using a wide set of biomarkers, including serum tumor markers; however, robust immune markers associated with efficacy have yet to be validated. In this study, changes in immune cell subsets
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ad2e68f4b7dfe4f532452ae3f1006291
https://doi.org/10.21203/rs.3.rs-863654/v1
https://doi.org/10.21203/rs.3.rs-863654/v1
Autor:
Tinne Verhulst, Lieven Meerpoel, Emmanuel Gustin, Weimei Sun, Matthew V. Lorenzi, Junchen Gu, Longen Zhou, Wim Bert Griet Schepens, Hillary Millar, Tongfei Wu, Viellevoye Marcel, Vineet Pande, Petra Vinken, Desiree De Lange, An Boeckx, Christopher Moy, Friederike Pastore, Geert Mannens, Sylvie Laquerre, Ulrike Philippar, Vipul Bhargava, Gaston Stanislas Marcella Diels, Thomas Nys, Kathryn Packman, Jan Willem Thuring, Erika van Heerde, Bie Verbist, Sumit Rai, Lijs Beke, Pegah Safabakhsh, Timothy A. Graubert, Yue Fan, Angelique N Gilbert, Dirk Brehmer, Vikki Keersmaekers, Barbara Morschhäuser, Danilo Fiore, David Walker, Amy J. Johnson
Publikováno v:
Molecular cancer therapeutics. 20(12)
The protein arginine methyltransferase 5 (PRMT5) methylates a variety of proteins involved in splicing, multiple signal transduction pathways, epigenetic control of gene expression, and mechanisms leading to protein expression required for cellular p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bff6d3af11d308608e3ab20a3144c14
https://pubmed.ncbi.nlm.nih.gov/34583982
https://pubmed.ncbi.nlm.nih.gov/34583982
Autor:
Anand D. Jeyasekharan, Tae-Hoon Chung, Adina Huey Fang Nee, Michelle Poon, Yen Lin Chee, Joanne Lee, Wee Joo Chng, Shuangyi Fan, Esther Chan, Nurulhuda Mustafa, Sabrina Hui Min Toh, Longen Zhou, Jing Yuan Chooi, Jennifer Yang, Viknesvaran Selvarajan, Siok Bian Ng
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
BackgroundThe potential therapeutic efficacy of daratumumab in natural killer T-cell lymphoma (NKTL) was highlighted when its off-label usage produced sustained remission in a patient with highly refractory disease. This is corroborated recently by a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04be32189a30cece55511d0798b4035a
https://doi.org/10.1136/jitc-2020-002123
https://doi.org/10.1136/jitc-2020-002123
Autor:
Heiko Konig, A. Richard Chamberlin, Wen-Hwa Lee, Chun-Mei Hu, Guideng Li, Phang Lang Chen, Erin M. Goldblatt, Xiao Long Qiu, Longen Zhou, Chi Fen Chen, Xiaoqin Lin, Ravi Bhatia, Guikai Wu, Jiewen Zhu
Publikováno v:
EMBO Molecular Medicine
Zhu, Jiewen; Zhou, Longen; Wu, Guikai; Konig, Heiko; Lin, Xiaoqin; Li, Guideng; et al.(2013). A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia. EMBO Molecular Medicine, 5(3), 353-365. doi: 10.1002/emmm.201201760. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/1g79t7jg
Zhu, Jiewen; Zhou, Longen; Wu, Guikai; Konig, Heiko; Lin, Xiaoqin; Li, Guideng; et al.(2013). A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia. EMBO Molecular Medicine, 5(3), 353-365. doi: 10.1002/emmm.201201760. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/1g79t7jg
RAD51 recombinase activity plays a critical role for cancer cell proliferation and survival, and often contributes to drug-resistance. Abnormally elevated RAD51 function and hyperactive homologous recombination (HR) rates have been found in a panel o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f14ac17cda2b21423a4bf2e416751dc
http://europepmc.org/articles/PMC3598077
http://europepmc.org/articles/PMC3598077
Autor:
Nurulhuda Mustafa, Adina Huey Fang Nee, Jennifer Yang, Viknesvaran Selvarajan, Sabrina Hui Min Toh, Longen Zhou, Jing Yuan Chooi, Wee Joo Chng, Yan Ting Hee
Publikováno v:
Blood. 132:1663-1663
Complement-dependent cytotoxicity (CDC) is one of the major mechanisms mediating the anti-tumor efficacy of Daratumumab. We have previously demonstrated that a majority of Natural Killer/T- Cell Lymphoma (NKTL) patient samples express CD38 and Daratu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12ecdea5d33e0dedf46cf7485b8218cb
https://doi.org/10.1182/blood-2018-99-115566
https://doi.org/10.1182/blood-2018-99-115566
Autor:
A. Richard Chamberlin, Guideng Li, Xiao-Long Qiu, Jiewen Zhu, Wen-Hwa Lee, Phang Lang Chen, Longen Zhou, Guikai Wu
Publikováno v:
Journal of Medicinal Chemistry. 52:1757-1767
High expression in cancer 1 (Hec1) is an oncogene overly expressed in many human cancers. Small molecule inhibitor of Nek2/Hec1 (INH) targeting the Hec1 and its regulator, Nek2, in the mitotic pathway, was identified to inactivate Hec1/Nek2 function
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cda0d3917e16efe935e72827f9df4ff
https://doi.org/10.1021/jm8015969
https://doi.org/10.1021/jm8015969